Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Brain Neoplasms 1702Glioblastoma 1308Glioma 995Neuroblastoma 408Central Nervous System Neoplasms 384Astrocytoma 384Gliosarcoma 286Oligodendroglioma 238Neoplasms 226Breast Neoplasms 216Meningioma 179Medulloblastoma 172Carcinoma, Non-Small-Cell Lung 149Recurrence 147Neoplasm Metastasis 138Lung Neoplasms 138Ependymoma 128Melanoma 119Sarcoma 117Neurofibromatosis 1 110Meningeal Carcinomatosis 107Lymphoma 95Neuroma, Acoustic 82Diffuse Intrinsic Pontine Glioma 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Head and Neck Neoplasms 79Ovarian Neoplasms 73Lymphoma, Follicular 73Pheochromocytoma 71Paraganglioma 68

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Acidophil × CNS × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡